Age-related decrease in expression of peroxisome proliferator-activated receptor α and its effects on development of dyslipidemia

Chinese Medical Journal

Volumn 118, Issue 13, 2005, Pages 1093-1098

  Ye, Ping ^a   Wang, Zhao Jun ^a   Zhang, Xiu Jin ^a   Zhao, Ya Li ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Ageing; Fenofibrate; Lipid; Peroxisome proliferator activated receptor

Indexed keywords

ACYL COENZYME A OXIDASE; APOLIPOPROTEIN C3; CARNITINE PALMITOYLTRANSFERASE; CHOLESTEROL; FENOFIBRATE; FIBRIC ACID DERIVATIVE; LIPOPROTEIN LIPASE; LONG CHAIN FATTY ACID COENZYME A LIGASE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRIACYLGLYCEROL;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG MECHANISM; DYSLIPIDEMIA; GENE EXPRESSION; GENE TARGETING; LIPID METABOLISM; LIVER; MALE; METABOLIC DISORDER; MOLECULAR MECHANICS; NONHUMAN; PROTEIN EXPRESSION; RANDOMIZATION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING;

AGING; ANIMALS; HYPERLIPIDEMIAS; LIPIDS; LIVER; MALE; PPAR ALPHA; PROCETOFEN; RATS; RATS, SPRAGUE-DAWLEY;

EID: 21844435990     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Knight JA. Biochemistry of aging. Adv Clin Chem 2001;35:1-62.
2. Michalik L, Wahli W. Peroxisome proliferator-activated receptors: three isotypes for a multitude of functions. Curr Opin Biotech 1999;10:564-570.
3. Bishop-Bailey D. Peroxisome proliferator-activated receptors in the cardiovascular system. Br J Pharmacol 2000;129:823-834.
4. Neve BP, Fruchart JC, Staels B. Role of the peroxisome proliferators-activated receptors ( PPAR ) in atherosclerosis. Biochem Pharmacol 2000;60:1245-1250.
5. Toth MJ, Tehernof A. Lipid metabolism in the elderly. Eur J Clin Nutr 2000;54 Suppl 3:S121-S125.
6. Watts GF, Dimmitt SB. Fibrates, dyslipoproteinemia and cardiovascular diseases. Curr Opin Lipidol 1999; 10:561-574.
7. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-418.
8. Gulick T, Cresci S, Caira T, et al. The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative gene expression. Proc Natl Acad Sci U S A 1994;91:11012-11016.
9. Akiyama TE, Nicol CJ, Fieve C, et al. Peroxisome proliferators-activated receptor-α regulates lipid homeostasis. J Biol Chem 2001;276:39088-39093.
10. Peters JM, Hennuyer N, Staels B, et al. Alteration in lipoprotein metabolism in peroxisome proliferator-activated receptor-α deficient mice. J Biol Chem 1997; 272:28307-28312.
11. Iemitsu M, Miyauchi T, Maeda S, et al. Aging-induced decrease in the PPAR-alpha level in hearts is improved by exercise training. Am J Physiol Heart Circ Physiol 2002;283:H1750-H1760.
12. Sangnino E, Bojarano R, Vazquez CM, et al. Increased triglyceride burden in old rats is originated by sex-related changes in liver expression of PPARα and biosynthetic enzymes. Proceedings of Second International Symposium on PPARs. Florence, Italy 2003;30.
13. Shetty S, Kummar A, Idell S. Post-transcriptional regulation of urokinase receptor mRNA: identification of a novel urokinase receptor mRNA binding protein in human mesothelioma cells. Mol Cell Biol 1997;19: 1075-1083.
14. Lavie CJ. Treatment of hyperlipidemia in elderly persons with exercise training, nonpharmacologic therapy, and drug combinations. Am J Geriatr Cardiol 2004;13(3 Suppl 1):29-33.